- IVF JAPAN Begins Preceptorship Program with AUGMENT Treatment -

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 14, 2015-- OvaScience^SM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the AUGMENT^SM fertility treatment is being offered in Japan through a preceptorship program at IVF JAPAN, one of the most prestigious fertility clinic systems in Japan. The initiation of the preceptorship program, in which patients will receive the AUGMENT treatment, follows approval from the Japan Society of Obstetrics and Gynecology (JSOG).

“The introduction of the AUGMENT treatment in Japan represents an important milestone for patients,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “We look forward to working to expand the availability of the AUGMENT treatment to women who experience poor egg health and are in need of new fertility treatment options.”

Under the leadership of Professor Yoshiharu Morimoto, M.D., Ph.D., IVF JAPAN conducts a combined 10,000 in vitro fertilization (IVF) cycles annually at its three clinics. Professor Morimoto is the President of the Pacific Society of Reproductive Medicine, the Past President of the Asia Pacific Initiative on Reproduction, the President of the Japan Society of Assisted Reproduction and the President of the Japan Society of Reproductive Psychology. Japan is the world’s largest IVF market, accounting for more than 326,000 IVF cycles annually.¹

IVF JAPAN is the first clinic network to offer the AUGMENT treatment in the region. The treatment is being offered through a preceptorship program, designed for the clinic to obtain patient experience and training before offering the treatment more broadly.

“Bringing forward innovative technologies on behalf of our patients is part of our mission at IVF JAPAN,” said Professor Morimoto, Chief Executive Officer of IVF JAPAN. “We are encouraged by the patient experiences with the AUGMENT treatment published to date, and look forward to seeing how it may improve the chance of success for women who are experiencing poor egg and embryo quality in our clinic.”

The AUGMENT treatment is not available in the United States.

About the AUGMENT^SM Treatment

The AUGMENT treatment is the first fertility treatment available to patients based on OvaScience’s proprietary egg precursor (EggPC^SM) cell technology. The AUGMENT treatment is designed to improve the health of a woman’s existing eggs and enhance the IVF procedure. The AUGMENT treatment uses energy-producing mitochondria from a woman’s own EggPC cells, which are immature egg cells found in the protective lining of the ovaries, to supplement the existing mitochondria in her eggs. This treatment is designed to improve egg health by increasing the eggs’ energy levels for embryo development. Egg health is a key factor in IVF success. The AUGMENT treatment is available in select international IVF clinics, and positive clinical experiences of pregnancies and births with the treatment have been reported. The AUGMENT treatment is not available in the United States. For more information, please visit www.augmenttreatment.com.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC^SM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT^SM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a preceptorship program with the OvaPrime^SM treatment, which could increase a woman’s egg reserve, and is developing the OvaTure^SM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the United States. For more information, please visit www.ovascience.com and www.augmenttreatment.com and connect with us on Twitter and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment and two fertility treatments in development, including statements relating to the expanded availability of the AUGMENT treatment and future use in Japan. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with, including those in Japan, may determine not to provide or continue providing the AUGMENT treatment, or to delay such treatment, based on clinical efficacy, safety or commercial, logistic, regulatory or other reasons; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

###

View source version on businesswire.com: http://www.businesswire.com/news/home/20151214005593/en/

Source: OvaScience

Media
OvaScience
Cara Mayfield, 617-714-9638
Director, Corporate Communications
cmayfield@ovascience.com
or
Michael Devine, 212-453-2324
michael.devine@fleishman.com